|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
86618 JD HEALTH-R
Nominal 
42.540 +0.560 (+1.334%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 73,441,487 | 26.275% | 58,159,881 | 53,529,941 | 46,736,150 | 30,682,267 |
| Cost of Sales | (55,242,325) | 23.168% | (44,851,304) | (41,664,605) | (36,844,642) | (23,484,985) |
| Gross Profit | 18,199,162 | 36.748% | 13,308,577 | 11,865,336 | 9,891,508 | 7,197,282 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (142,786) | -54.794% | (315,853) | (69,859) | (98,202) | (38,352) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (64,050) | -25.111% | (85,527) | (70,757) | (96,759) | (94,165) | |
| Profit / (Loss) before Taxation | 6,029,995 | 25.712% | 4,796,676 | 2,693,348 | 695,809 | (901,491) | |
| Taxation | (662,886) | 3.631% | (639,662) | (550,468) | (312,580) | (171,327) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 8,296 | 71.760% | 4,830 | (1,039) | (3,124) | (689) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 5,375,405 | 29.159% | 4,161,844 | 2,141,841 | 380,105 | (1,073,507) | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (1,526,436) | -21.814% | (1,952,308) | (1,939,547) | (855,167) | (451,570) |
| Depreciation & Amortisation | 279,989 | 30.412% | 214,695 | 227,458 | 140,676 | 63,169 |
| Directors' Emoluments | -- | -- | 276,896 | 418,439 | 664,846 | 1,062,758 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 170.000 | 28.788% | 132.000 | 69.000 | 12.000 | -35.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 1.379 | 1.474 | 1.901 | 1.109 |
| NBV per share ($) | 18.718 | -- | 17.267 | 15.479 | 14.082 | 12.475 |
| Remarks: | Real time quote last updated: 06/03/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 5,375,405 |
| %Change | 29.159% |
| EPS / (LPS) | RMB 1.700 |
| NBV Per Share (¥) | RMB 18.718 |